Nakano City

This research aims to assess the safety and effectiveness of Fabhalta capsules in patients diagnosed with C3 glomerulopathy, including those who have experienced recurrence after a kidney transplant. The study focuses on real-world clinical practice to better understand how Fabhalta performs in managing this condition. The study involves patients who have already been treated with Fabhalta for C3 glomerulopathy. There are no additional interventions or comparator groups described, as the study is observational and monitors the outcomes of those using Fabhalta. Participants will be followed for up to 360 days, during which researchers will track the number of patients who develop infections. This monitoring helps evaluate the safety profile of Fabhalta over time. No other specific assessments or procedures are detailed in the study information provided.